Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1HR+/HER2- Advanced Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1

Interventions

Cisplatin 9pembrolizumab 7Irinotecan 7Radiotherapy 6Fluorouracil 6Docetaxel 5spartalizumab 4Oxaliplatin 4130-nm albumin-bound paclitaxel 4Nivolumab 3Carboplatin 3toripalimab 2tislelizumab 2elgemtumab 2durvalumab 2Radiation 2Paclitaxel 2Leucovorin 2Gemcitabine 2Drug Therapy 2vandetanib 1tremelimumab 1ribociclib 1palbociclib 1obinutuzumab 1nedaplatin 1nazartinib 1naptumomab estafenatox 1liposomal doxorubicin 1dalpiciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Esophageal Squamous Cell Carcinoma × dalpiciclib × Clear all
NCT06225921 2024-03-06

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

West China Hospital

Phase 1 Unknown
6 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡